Targeting ASCT2-Mediated Glutamine Uptake Blocks Prostate Cancer Growth and Tumour Development

Abstract

Qian Wang\textsuperscript{1,2,3}, Rae-Anne Hardie\textsuperscript{1,2,3}, Andrew J. Hoy\textsuperscript{4}, Michelle van Geldermalsen\textsuperscript{1,2,3}, Dadi Gao\textsuperscript{2,3,5}, Ladan Fazli\textsuperscript{6}, Martin C. Sadowski\textsuperscript{7}, Seher Balaban\textsuperscript{4}, Mark Schreuder\textsuperscript{4}, Rajini Nagarajah\textsuperscript{1,2,3}, Justin J-L Wong\textsuperscript{2,3}, Cynthia Metierre\textsuperscript{2,3}, Natalia Pinello\textsuperscript{2,3}, Nicholas J. Otte\textsuperscript{1,2,3}, Melanie L. Lehman\textsuperscript{7}, Martin Gleave\textsuperscript{6}, Colleen C. Nelson\textsuperscript{7}, Charles G. Bailey\textsuperscript{2,5}, William Ritchie\textsuperscript{2,3,5}, John E.J. Rasko\textsuperscript{2,3,8}, Jeff Holst\textsuperscript{1,2,3}

\textsuperscript{1}Origins of Cancer Laboratory, Centenary Institute, Camperdown, NSW, 2050, Australia
\textsuperscript{2}Sydney Medical School, University of Sydney, NSW, 2006, Australia
\textsuperscript{3}Gene and Stem Cell Therapy Program, Centenary Institute, Camperdown, NSW, 2050, Australia
\textsuperscript{4}Discipline of Physiology, Bosch Institute and Charles Perkins Centre, University of Sydney, NSW, 2006, Australia
\textsuperscript{5}Bioinformatics, Centenary Institute, Camperdown, NSW, 2050, Australia
\textsuperscript{6}Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V6H 3Z6, Canada
\textsuperscript{7}Australian Prostate Cancer Research Centre-Queensland, Queensland University of Technology, Australia
\textsuperscript{8}Cell and Molecular Therapies, Royal Prince Alfred Hospital, Camperdown, NSW, 2050, Australia

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/path.4518

This article is protected by copyright. All rights reserved
**Corresponding author:** Jeff Holst, Origins of Cancer Laboratory, Centenary Institute, Locked Bag 6, Newtown, NSW 2042 Australia. Phone: +61 2 9565 6172; E-mail: j.holst@centenary.org.au

**Disclosure of Potential Conflict of Interest:** No potential conflicts of interest were disclosed.
Abstract

Glutamine is conditionally essential in cancer cells, being utilized as a carbon and nitrogen source for macromolecule production as well as for anaplerotic reactions fueling the tricarboxylic acid (TCA) cycle. In this study, we demonstrate the glutamine transporter ASCT2 (SLC1A5) is highly expressed in prostate cancer patient samples. Using LNCaP and PC-3 prostate cancer cell lines, we show that chemical or shRNA-mediated inhibition of ASCT2 function \textit{in vitro} decreases glutamine uptake, cell cycle progression through E2F transcription factors, mTORC1 pathway activation and cell growth. Chemical inhibition also reduces basal oxygen consumption and fatty acid synthesis, showing that downstream metabolic function is reliant on ASCT2-mediated glutamine uptake. Furthermore, shRNA knockdown of ASCT2 in PC-3 cell xenografts significantly inhibits tumour growth and metastasis \textit{in vivo}, associated with the down-regulation of E2F cell cycle pathway proteins. In conclusion, ASCT2-mediated glutamine uptake is essential for multiple pathways regulating cell cycle and cell growth, and is therefore a putative therapeutic target in prostate cancer.

Keywords: ASCT2; SLC1A5; glutamine; cell cycle; metabolism; prostate cancer
Introduction

Glutamine is the most abundant amino acid in plasma, functioning as a critical source of nitrogen and carbon in cells. The metabolic shift in cancer, however, imparts a new ability on the cells to utilize glutamine as an alternative fuel source to glucose for the tricarboxylic acid (TCA) cycle, and as a source of fatty acid production through reductive carboxylation [1-3]. Many of these changes in glutamine metabolism directly result from oncogenic transformation, such as Myc amplification [4-6], commonly seen in prostate cancer [7].

Another important role for amino acids is to control signaling through the nutrient sensor mTORC1. The tumour suppressor gene, PTEN, is commonly mutated or deleted in prostate cancer [8], leading to up-regulation of the PI3K/Akt/mTORC1 signaling pathway. The amount of intracellular amino acids such as leucine determines the activity of mTORC1 through Rag complexes on the lysosome surface [9-13]. In combination with leucine, glutamine has also been shown to be critical for mTORC1 signaling by enhancing glutaminolysis and α-ketoglutarate production [14]. This link is further supported by the role of glutamine in facilitating leucine transport [15], and the feedback generated by activation of mTORC1, which promotes glutaminolysis in cancer [3].

The major glutamine transporter in cancer cells is alanine-serine-cysteine transporter-2 (ASCT2; SLC1A5)(26-28). ASCT2 is a Na⁺-dependent, broad-scope neutral amino acid exchanger that belongs to solute carrier (SLC) family-1, which mediates the obligatory exchange of substrate amino acids, including alanine, serine, cysteine, threonine, glutamine and asparagine [16]. ASCT2 is expressed in the normal prostate and in prostate cancer [17]. Previous studies have shown that ASCT2 function is important for cancer cell growth in
melanoma [18], acute myeloid leukemia [19], lung cancer [20], neuroblastoma [21] and pancreatic ductal carcinoma [22].

In this study, we show ASCT2 expression is increased in prostate cancer patient samples, and that knockdown inhibits cell cycle progression, prostate cancer growth and spontaneous metastasis \textit{in vivo}. ASCT2 chemical inhibitors also suppressed glutamine transport, cell growth and glutamine metabolism \textit{in vitro}. Our study suggests that compounds targeting ASCT2 may provide novel therapeutics for prostate cancer.
Materials and Methods

Please see online Supplementary Information for additional Materials and Methods.

Patient specimens

Prostate cancer specimens from radical prostatectomy (n=194) were obtained from the Vancouver Prostate Centre Tissue Bank (http://www.prostatecentre.com/our-research/core-facilities/biorepository). This project was approved by the institutional review boards at the University of British Columbia (Vancouver, Canada) and the CHUQ Research Centre (Québec, Canada). Written informed consent was obtained from all participants. The Haematoxylin & Eosin (H&E) slides were reviewed and desired areas were identified on paraffin blocks. Tissue microarrays (TMAs) were manually constructed (Beecher Instruments, MD, USA) by punching duplicate cores of 1 mm for each sample, with quantitative analysis calculated from individual cores (individual Gleason score) or the average of duplicate cores (NHT TMA analysis).

TMA Immunohistochemistry

TMA staining was conducted using a Ventana auto-stainer model Discover XT™ with an enzyme-labeled biotin streptavidin system and solvent resistant DAB Map kit, using a 1:4000 dilution of rabbit anti-SLC1A5 (HPA035240). Staining was graded by a pathologist (LF) using a semi-quantitative four point scale where 0 represents no staining, 1 faint or focal staining, 2 moderate intensity in at least a quarter of neoplastic cells, and 3 intense staining in the majority of neoplastic cells. Examples of the staining are shown in Supplementary Fig. S1B.

Cell culture and uptake assay

Human prostate cancer cell lines LNCaP-FGC, PC-3 and DU145 were purchased from ATCC (Rockville, MD). LNCaP cells have been passaged directly from original low-passage
stocks (2009), and we confirmed PC-3, LNCaP and DU145 cell identity by STR profiling in 2010 and 2014 (Cellbank, Sydney). Cells were cultured in RPMI 1640 medium containing 10% (v/v) fetal bovine serum (FBS), penicillin-streptomycin solution and 1 mM sodium pyruvate. Cells were maintained at 37°C in an atmosphere containing 5% CO₂. Chemicals were diluted as follows, with control wells treated with the appropriate vehicle controls: H-Ser(Bzl)-OH (BenSer; Bachem; diluted in H₂O), l-γ-glutamyl-p-nitroanilide (GPNA; MP Biochemicals; diluted in H₂O), bicalutamide (AstraZeneca; diluted in DMSO). The [³H]-L-leucine and [³H]-L-glutamine uptake assays were performed as detailed previously [18, 32].

**Knockdown of ASCT2**

ASCT2 shRNA knockdown was performed as previously described [18]. Two different shRNAs for ASCT2 were used in this study (Sigma), shASCT2#1 (CCGGGCTGCTTATCCGCTTCTTCAACTCGAGTTGAAGAAGCGGATAAGCTTTTG). shASCT2#2 (CCGGCTGGATTATGAGGAATGGATACTCGACTGATGATCCATTCCCTCATAATCCAGTTTTTG).

**Gene Expression Analysis**

PC-3 cells were incubated in the presence or absence of GPNA or BenSer for 48 h, cells harvested and total RNA was extracted from cells using Trizol. RNA quality was confirmed (RIN values 9.8-10) using RNA 6000 Nano Chips on an Agilent 2100 Bioanalyzer (Agilent Technologies). Libraries were prepared using TruSeq Stranded Total RNA kit (Illumina, San Diego) and paired end sequencing was performed on an Illumina HiSeq 2500 at The Kinghorn Cancer Centre (Sydney). Paired-end RNA-sequencing reads were trimmed and mapped to annotated human genome (hg19/GRCh37.p13) using Tophat2 with default settings. For each gene, the number of reads were counted and normalized to the library size. The threshold for expression was set at 5 reads in at least one experimental group. Exact tests were applied to compare differences in the means of read-counts from 4 replicates between
the treated and untreated group. The gene expression levels were estimated in CPM (count-per-million-read). The National Center for Biotechnology Information Gene Expression Omnibus number for mRNA sequencing data sets described in this study is GSE65112.

**PC-3-luc xenografts and bioluminescence imaging**

Athymic (nu/nu) male nude mice (Animal Resource Center, Perth, Australia) 6-8 weeks of age were housed in a specific pathogen-free facility in accordance with the University of Sydney animal ethics committee guidelines. Mice were anaesthetized via 2% isoflurane inhalation and received subcutaneous (s.c.) injections of $1 \times 10^6$ PC-3-luc cells resuspended in 100 μL of Hank’s Balanced Salt solution (HBSS). Xenografts were transplanted in both the right and left side ventral flanks of mice as detailed previously [30]. Tumour growth was monitored via bioluminescence imaging performed 48 h following cell implantation and bi-weekly thereafter for 32 days. During the experiments, two shASCT2 mice were dead after 4 days injection due to fighting. They were not included in the analyses. Anaesthetized mice received intraperitoneal (i.p.) injections of D-luciferin substrate (150 mg/kg in DPBS, Gold Biotechnology) and images were acquired after a 15 min interval, using the Xenogen in vivo imaging system (IVIS) Lumina II (Caliper life science, MA, USA). Regions of interest were determined using Living Image Software (Caliper life science, MA, USA) and quantified in photons per second (p/s). After 32 days, animals were sacrificed following the final imaging time point. Livers and lungs were removed for IVIS-Lumina II analysis to detect spontaneous metastases. After being imaged and weighed, tumours were collected either in Trizol for RNA analysis, lysis buffer for western blotting analysis or fixed in 10% (v/v) neutral buffered formalin for sectioning and immunostaining.

**Statistical analysis**

Data are expressed as mean ± SEM. All experiments were performed with at least 3 replicate experiments, and analyzed using a Mann-Whitney U-test or one-way ANOVA test in
GraphPad Prism v6. MTT assay and tumour growth curve analysis used the two-way ANOVA test. Tumour metastasis analysis used the Fisher’s exact test. All statistical tests were two-sided.
Results

ASCT2 expression is increased in prostate cancer

To determine whether ASCT2 expression is increased in prostate cancer compared to normal tissue, we compared patient-matched TCGA mRNA expression data for normal prostate vs prostate cancer (Fig. 1A). There was a significant increase in ASCT2 expression in tumour samples compared to normal (pairwise t-test; $P=0.025$), with 24/36 patients showing increased tumour ASCT2 levels compared to patient-matched normal prostate tissue ($\chi^2$ test; $P=0.046$). Analysis of Oncomine datasets showed significant increases in ASCT2 expression ($P<0.05$) in seven prostate cancer datasets (Table 1). To determine ASCT2 protein levels, we performed immunohistochemical staining on a human prostate cancer tissue microarray (TMA; Fig. 1B). At all stages of prostate cancer, ASCT2 protein was detected in the membrane of the prostate epithelial cells, but not in the cytoplasm (Supplementary Fig. S1A).

There were no significant differences in expression between Gleason grades in either the TMA or TCGA dataset (Supplementary Fig. S1B and C). Comparing untreated with patients undergoing neoadjuvant hormone therapy (NHT), a significant decrease in ASCT2 protein expression was observed in 1-6 and 7-12 months treatment ($P=0.04$; $P<0.001$; Fig. 1C). This supports previous data showing that ASCT2 expression is regulated by the androgen receptor [23]. Interestingly, ASCT2 expression significantly increased in patients with recurrent prostate cancer ($P<0.001$; Fig. 1C), indicating either re-activation of androgen receptor signaling, or that other signaling pathways might up-regulate ASCT2 expression upon disease recurrence. Analysis of an LNCaP xenograft model [24] at various stages pre-castration (intact), post-castration during regression, at the nadir of PSA, in recurrent and castration-resistant prostate cancer (CRPC) further confirmed this dynamic regulation of ASCT2 expression. ASCT2 expression significantly decreased post-castration (regression and nadir), before increasing in recurrent and CRPC, where ASCT2 expression was no longer
significantly different from intact ASCT2 levels (Fig. 1D). These human and xenograft data suggest that ASCT2 levels may be important in both the primary tumour as well as during tumour recurrence and CRPC.

**Inhibition of ASCT2 suppresses prostate cancer cell growth**

Analysis of ASCT2 protein showed high expression in both LNCaP and PC-3 cells, with lower levels detected in DU145 cells (Fig. 2A). Addition of the ASCT2 competitive inhibitor benzylserine (BenSer; Supplementary Fig. S2A) [25], significantly reduced both glutamine uptake and leucine uptake in LNCaP, PC-3 and DU145 cells (Fig. 2B and C). Leucine uptake inhibition occurs due to exchange of glutamine for leucine by L-type amino acid transporter 1 (LAT1; SLC7A5), but may also be through direct LAT1 inhibition [15]. Inhibition of androgen receptor signaling by bicalutamide also significantly reduced glutamine uptake in androgen-sensitive LNCaP cells but not androgen-insensitive PC-3 cells (Supplementary Fig. S2B and C), confirming that AR signaling regulates ASCT2 levels [23] and ASCT2-mediated glutamine transport. After three days treatment with BenSer, cell growth was significantly decreased in LNCaP, PC-3 and DU145 cells (Fig. 2D). We have previously shown LAT1 inhibition affects cell cycle through E2F-regulated cell cycle proteins CDK1, CDC20 and UBE2C [23]. These three cell cycle regulatory proteins are also significantly increased in prostate cancer metastasis [23]. CDK1, CDC20 and UBE2C also exhibited decreased expression after BenSer treatment (Fig. 2E).

**Inhibition of ASCT2 suppresses glutamine metabolism in prostate cancer**

As leucine and glutamine are involved in activation of mTORC1 signaling [14, 26, 27], we examined T389 phosphorylation of p70S6K, a downstream target of mTORC1. BenSer reduced the phosphorylation of p70S6K in PC-3 cells, but not in LNCaP cells (Fig. 2F). Utilizing another ASCT2 inhibitor, l-γ-glutamyl-p-nitroanilide (GPNA; Supplementary Fig
S2D)[28], confirmed that glutamine deprivation inhibits mTORC1 pathway in PC-3 cells but not LNCaP cells (Fig. 2F). These data suggested that mechanisms other than mTORC1 must also contribute to regulate cell growth in prostate cancer.

The majority of intracellular glutamine is converted into glutamate, which can be utilized by the TCA cycle for ATP and fatty acid production or exported from the cell by xCT (SLC7A11) in exchange for cystine, thereby contributing to glutathione production and protection against oxidative stress. Alternatively, glutamine acts as a nitrogen and carbon donor for macromolecular synthesis including nucleotides and non-essential amino acids/proteins. We therefore set out to determine how changes in intracellular glutamine affect these downstream pathways. Using the Seahorse flux analyzer, BenSer or GPNA treatment resulted in a reduction in basal oxygen consumption rates (OCR) compared to control in LNCaP and PC-3 cells (Supplementary Fig. S2E and F). GPNA, but not BenSer, significantly reduced basal OCR in both LNCaP and PC-3 cells (Fig. 3A and B). However, this reduction in OCR did not appear to directly result from glutamine usage, as there was no significant reduction in oxidized 14C-labelled glutamine in either cell line after BenSer or GPNA (Fig. 3C and D), despite lower 14C-glutamine uptake (Supplementary Fig. S2G and H).

Lipid synthesis from glutamine, however, was significantly decreased in LNCaP cells (Fig. 3E), but not PC-3 cells (Fig. 3F). These data suggest that LNCaP cells directly utilize glutamine for fatty acid synthesis, while PC-3 cells may utilize glutamine for other pathways, including exchange for leucine (Fig. 2C) to activate mTORC1 signaling (Fig. 2F), which indirectly affects mitochondrial respiration.

To further investigate lipid homeostasis, we measured the levels of cellular phospholipids and neutral lipids. Lipid content analysis of LNCaP cells revealed that GPNA significantly reduced the cellular level of phospholipids (Fig. 3G) and BenSer and GPNA reduced the neutral lipids (Fig. 3I) as well as lipid droplet number (Fig. 3K). Notably, the magnitude of
inhibition by BenSer and GPNA was similar to 5-(tetradecyloxy)-2-furoic acid (TOFA), which inhibits the rate-limiting enzyme of fatty acid synthesis, Acetyl-CoA carboxylase (Fig. 3G, I and K). A significant decrease of phospholipids was also observed in PC-3 cells (Fig. 3H), however there was no significant decrease in neutral lipids (Fig. 3J) or lipid droplet numbers (Fig. 3L). Taken together, pharmacological inhibition of ASCT2 provoked cell linespecific effects on the flux of glutamine as a fuel source, yet ultimately led to reduced OCR and cellular lipid levels in both prostate cancer cell lines. However, neither BenSer nor GPNA led to increased levels of reactive oxygen species (ROS; Supplementary Fig. S2I).

**Global effects of BenSer or GPNA inhibition in PC-3 cells**

To determine the global effects of ASCT2 inhibition, we used next generation sequencing to determine mRNA expression changes in PC-3 cells treated with BenSer or GPNA for 48 h. Analysis of genes significantly (*P*<0.05) up- or down-regulated by GPNA (Supplementary Table S1) compared to control showed a substantial overlap (up-regulated, 45.1%; down-regulated, 49.7%) with BenSer gene expression, highlighting common targets of ASCT2 (Fig. 4A). BenSer appears to have additional non-ASCT2 mediated affects, with more genes showing significant up- and down-regulation (Supplementary Table S2) compared to GPNA (Fig. 4A). This is not surprising, since BenSer has been shown to inhibit both ASCT2 and LAT1 function in oocytes [18].

Gene set enrichment analysis (GSEA) using Gene Ontology categories showed significant enrichment in control compared to GPNA for RNA and DNA processing and metabolism, as well as cell cycle processes (Fig. 4B; Supplementary Table S3). Similar categories were also enriched in control compared to BenSer (Fig. 4C; Supplementary Table S4). Analysis of motif enrichment by GSEA showed a significant association with E2F transcription factor
motifs for control compared to either GPNA or BenSer (Fig. 4D and E; Supplementary Table S5 and S6). We have previously shown that inhibition of leucine uptake in LNCaP cells shows similar E2F mediated cell cycle inhibition, with a subset of 122 genes down-regulated by the leucine uptake inhibitor BCH [23]. Analysis of this 122-gene signature in control vs GPNA and BenSer showed significant enrichment in the control group (Fig. 4F and G), suggesting there is a common mechanism regulating gene expression after leucine starvation and glutamine starvation in prostate cancer.

Amino acid starvation leads to up-regulation of the stress-response transcription factor ATF4, which in turn leads to increased expression of diverse amino acid transporters, including ASCT2 and LAT1 [23]. ATF4 was the 1st \((P=1.10E-11)\) and 16th \((P=4.21E-21)\) most significantly up-regulated gene in GPNA- or BenSer-treated cells respectively (Supplementary Table S1 and S2), which was verified by qRT-PCR (Supplementary Fig. S3A and B). ATF4 has previously been shown to directly transcriptionally regulate the expression of transporters including ASCT2, ASCT1, xCT and SLC3A2 [23, 29]. Analysis of gene sets up-regulated after GPNA inhibition showed significant enrichment for Gene Ontology categories including amino acid transport (Supplementary Fig. S3C), with significant up-regulation of transporters including SLC1A5 (ASCT2, \(P=0.020\)), SLC1A4 (ASCT1; \(P=7.72E-5\)), SLC7A11 (xCT; \(P=7.02E-8\)), SLC38A1 (SNAT1; \(P=3.51E-5\)), SLC7A8 (LAT2; \(P=5.63E-5\)), SLC3A2 (4F2hc; \(P=0.041\)) and SLC3A1 (\(P=0.005\)). Another critical gene significantly increased by both GPNA (\(P=0.009\)) and BenSer (\(P=0.0002\)) was EIF2AK3 (PERK), which can phosphorylate eIF2α leading to a global protein synthesis suppression. A set of genes that belong to eukaryotic translation initiation factor are significantly decreased after GPNA treatment, including EIF3B (\(P=0.0003\)), EIF2A (\(P=0.003\)), EIF4H (\(P=0.005\)), EIF5A (\(P=0.009\)), EIF2B3 (\(P=0.034\)), EIF4G1 (\(P=0.039\)), EIF2B4 (\(P=0.040\)) and EIF2B5 (\(P=0.048\)).
Knockdown of ASCT2 suppresses growth in prostate cancer cells

We used lentiviral shRNA-mediated knockdown of ASCT2 to substantiate the direct ASCT2 effects of BenSer and GPNA in LNCaP and PC-3 cells. Two different shRNAs decreased ASCT2 expression and glutamine transport in LNCaP and PC-3 cells compared to a non-targeting shRNA control (Fig. 5A and B; Supplementary Fig. S3D). Inhibition using shASCT2#2 also significantly decreased leucine uptake in both LNCaP and PC-3 cells (Fig. 5C), suggesting that ASCT2-transported glutamine is utilized for leucine uptake.

LNCaP and PC-3 cells expressing shASCT2#2 showed a significant decrease in cell viability compared to shControl cells (Fig. 5D and E). Analysis of BrdU incorporation (Fig. 5F) and apoptosis (Supplementary Fig. S3E) in shASCT2#2-expressing PC-3 cells, confirmed that ASCT2 knockdown inhibits cell cycle rather than apoptosis. Similar results for glutamine uptake, BrdU incorporation and apoptosis were also observed in shASCT2#1 PC-3 cells (Supplementary Fig. S3D, F and G). Finally, we examined mTORC1 pathway activation by western blotting, showing reduced phosphorylation of p70S6K in PC-3 cells expressing shASCT2#2 (Fig. 5G).

Knockdown of ASCT2 suppresses tumour growth in prostate cancer xenografts

To determine whether ASCT2 function is critical for tumour growth in vivo, PC-3 cells expressing shControl or shASCT2#2 were transduced with a lentiviral vector coexpressing eGFP and firefly luciferase [30]. Cells were enriched to high purity on a narrow band of high GFP expression, resulting in similar GFP/luciferase expression in each shControl and shASCT2 cell line (Supplementary Fig. S4A). PC-3luc cells were subcutaneously injected into nude mice, with similar luciferase expression in shControl and shASCT2 tumours confirmed after 48 h (Fig. 6A). Bioluminescence was analyzed twice per week for 32 days, showing a significant decrease in shASCT2 tumour size by day 25 (Fig. 6B).
Mice were euthanized after 32 days due to the size of shControl tumours. The tumours were isolated, photographed and weighed, with shControl tumours being significantly larger than shASCT2 tumours (Fig. 6C and D; $P<0.001$). Western blots of xenograft tumours showed that phosphorylation of p70S6K was decreased in shASCT2 tumours compared to shControl tumours (Fig. 6E). Analysis of E2F2, CDK1, CDC20, UBE2C, as well as the proliferation biomarker Ki67 in xenograft sections showed consistently lower levels in the shASCT2 tumours (Fig. 6F). There were no changes in cleaved caspase 3 levels (Supplementary Fig. S4B).

Micro-metastases were detected by isolation and ex vivo bioluminescence analysis of organs immediately after euthanasia (Supplementary Fig. S4C). Analysis of shControl mice showed 9/10 had metastases in the liver and 4/10 in the lung, while shASCT2 mice showed 4/9 had metastases in the liver, with no lung metastases ($P=0.004$; Fig. 6G). Metastatic bioluminescence burden in the liver and lung also showed a significant decrease in shASCT2 xenografted mice (Fig. 6H).
Discussion

ASCT2 can be regulated by multiple transcription factors including Myc [6], Rb/E2F [31], androgen receptor [23] and ATF4 [21, 23]. This permits similar ASCT2 protein expression in both androgen-dependent (LNCaP) and androgen-independent (PC-3) prostate cancer cell lines, and facilitates sufficient glutamine for cell growth. Our patient and LNCaP xenograft data confirmed that androgen receptor regulation of ASCT2 contributes to its expression in untreated/primary cancer, and that under androgen deprivation therapy, ASCT2 levels decrease. Similar to other androgen receptor- and ATF4-regulated genes [23], re-expression of ASCT2 was observed in recurrent disease. Importantly, ATF4 levels are significantly increased in androgen-independent prostate cancer metastasis compared to primary cancer (2.25 fold, \( P=3.82E-7 \)) [23], suggesting that activation of ATF4 transcriptional targets is important in either metastasis or maintenance of the metastatic tumour. Interestingly, ASCT2 knockdown tumours showed decreased metastasis in the liver and lung, although this is confounded by the smaller primary tumours.

Blocking ASCT2 using either chemical or genetic means reduced cell proliferation and cell cycle in both LNCaP and PC-3 cell lines. This coincided with not only reduced glutamine levels, but also a reduction in the essential amino acid leucine, likely through LAT1 mediated exchange for leucine. Although knockdown of ASCT2 resulted in similar glutamine uptake inhibition in LNCaP and PC-3 cells, leucine uptake was inhibited at a higher level in PC-3 cells, coincident with the higher LAT1 expression compared to LNCaP cells [32], further supporting the ASCT2/LAT1 exchange hypothesis, which subsequently leads to altered mTORC1 signaling [15, 33]. ASCT2 inhibition did not directly alter glutamine metabolism in PC-3 cells, suggesting that the effects on basal OCR may be due to combined glutamine/leucine inhibition, and subsequent shut down of energy consuming processes such as protein, lipid, RNA and DNA synthesis. Previous studies have shown that mTORC1...
controls mitochondrial activity through 4EBP-dependent translation regulation [34] and mitochondrial gene expression [35]. This mechanism is further supported by the GPNA-mediated down-regulation of GO categories for RNA and DNA Processing and Mitochondrial Genesets in PC-3 cells. Analysis of glutamine metabolism in LNCaP cells, however, showed that inhibition of ASCT2 suppresses basal oxygen consumption, as well as TCA cycle glutaminolysis through complete oxidation and conversion to lipids. LNCaP cells have low expression of LAT1, and high expression of the leucine uniporter LAT3, and thereby are not as reliant on glutamine exchange to maintain leucine levels. They appear more reliant on glutamine anaplerosis than PC-3 cells.

Analysis of gene expression in PC-3 cells treated with BenSer or GPNA showed an adaptive response to glutamine deprivation through ATF4-mediated transcription, resulting in reduced cell cycle and RNA processing, and up-regulation of amino acid transporters in an attempt to restore glutamine levels. Previous studies have suggested that targeting this ATF4 mediated stress response may provide an effective cancer therapy [36]. However, in glioblastoma, the ATF4 response to glutamine deprivation directs apoptosis through NOXA and PUMA [37]. Unlike glioblastoma, we did not observe an increase in apoptosis in PC-3 cells after ASCT2 inhibition. These chemicals, or ASCT2 shRNA knockdown, do not induce complete glutamine deprivation, suggesting that perhaps the magnitude of glutamine deprivation, and subsequent ATF4 activation, may be critical in driving cell fate decisions for survival or apoptosis.

High expression of ASCT2 has previously been reported in the normal prostate [17], and many rapidly dividing normal cells rely on ASCT2 expression for glutamine uptake. Despite this important function in normal cells, the ASCT2 knockout mice do not show any obvious abnormalities in growth or survival, making ASCT2 an attractive therapeutic target [40]. Compared to the immunosuppressive effects of directly inhibiting mTORC1, the ASCT2
knockout mice have a relatively mild immune phenotype involving Th1 and Th17 lineage
differentiation [40]. Despite this mild phenotype, it will still be important to monitor immune
cells and effects on other normal cells when developing ASCT2-targeted therapies.

Our in vivo knockdown data support the development of ASCT2 as a therapeutic target in
prostate cancer. Since ASCT2 is androgen regulated, one could envisage targeting ASCT2 in
either primary or advanced prostate cancer. Importantly, our data showed that targeting
ASCT2 not only inhibited known pathways such as mTORC1, but also regulated critical
metastasis-expressed E2F-regulated cell cycle genes CDK1, CDC20 and UBE2C, thereby
resulting in a two-pronged block of cell division. This suggests that ASCT2 targeted therapies
may be particularly effective in advanced castration-resistant prostate cancer. However,
current ASCT2 inhibitors, such as BenSer [38], GPNA [28] and dithiazoles [39], have high
effective concentrations rendering them ineffective as putative therapeutics. The development
of new inhibitors in the low μM or nM range would be required for further preclinical testing.
This is one of the major limitations of this current study. Additionally, once a drug is
developed, it would be important to determine an appropriate clinical population and setting
that may benefit from ASCT2 targeting, using preclinical models such as patient-derived
xenografts or explants. Further limitations surround the potential upregulation of other
 glutamine transporters by adaptive mechanisms such as ATF4 transcription. This will need to
be monitored for potential compensation mechanisms in tumours. Finally, while glutamine is
clearly an important amino acid transported by ASCT2, it remains to be determined what
downstream effects are caused by inhibition of other ASCT2-transported amino acids such as
alanine, serine, cysteine, threonine, or asparagine.

In summary, we have shown that ASCT2 is the key glutamine transporter that regulates
prostate cancer proliferation and metabolism. We have identified critical cell cycle and
metabolic pathways, which may provide new avenues for therapeutic intervention in prostate cancer.
Acknowledgements

We thank Frank Kao from Flow Cytometry Support in Centenary Institute for cell sorting. We thank The Kinghorn Cancer Centre for Library preparation and Next Generation Sequencing. This work was supported by grants from Movember through the Prostate Cancer Foundation of Australia (YI0813 to Q.W.; PG2910 to J.H.; YI0707 to J.H.; and the Australian Movember Revolutionary Team Award Targeting Advanced Prostate Cancer, J.H., Q.W., M.C.S, C.C.N. and M.L); National Breast Cancer Foundation (ECF-12-05 J.H.); National Health and Medical Research Council (1051820 to J.H.); Cure the Future and an anonymous foundation (J.E.J.R); Tour de Cure Fellowship (C.G.B); Cancer Institute NSW Fellowships (J.J-L.W and W.R).

Authors’ Contributions

Conception and design: J. Holst, Q. Wang

Development of methodology: J. Holst, Q. Wang, C.G. Bailey, W. Ritchie


Writing, review, and/or revision of the manuscript: J. Holst, Q. Wang, J.E.J. Rasko, C.G. Bailey

Study supervision: J. Holst
References


Figure legends

Figure 1

A

B

C

D

Figure legends
Figure 1. ASCT2 is androgen receptor-regulated and expressed in prostate cancer patient samples and xenografts. A, ASCT2 mRNA expression in matched prostate cancer samples compared to adjacent normal prostate from the TCGA dataset (Data are mean ± SEM, Paired t-test; n=36). B, representative images of ASCT2 protein expression in prostate cancer patient samples from Gleason grade 3, Gleason grade 4, Gleason grade 5 and after neoadjuvant hormone therapy (NHT) treatment following an interval of 1-6 months, 7-12 months and in recurrent cancer. Scale bar is 100 µm. C, Immunohistochemical scoring of ASCT2 expression in patient cohorts before (n=46) and after NHT treatment for 1-6 months (n=54), 7-12 months (n=76) and recurrent cancer (n=32). Data are mean ± SEM, Mann-Whitney U-test. D, microarray analysis of ASCT2 mRNA expression from LNCaP xenograft tumours harvested from noncastrated mice (intact; n=10), post-castration regressing tumours (regressing; n=6), at PSA nadir after castration (nadir; n=10), after recurrent prostate cancer had developed (recurrent; n=6), and castration-resistant prostate cancer (CRPC; n=13). Data are mean ± SEM, Mann-Whitney U-test. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Figure 2. Inhibition of ASCT2-mediated glutamine transport in prostate cancer cell lines. A, ASCT2 protein was detected by western blotting in LNCaP, PC-3 and DU145 cell lines. B-C, the effect of BenSer (10 mM) on glutamine transport (B) and leucine transport (C) in LNCaP, PC-3 and DU145 cell lines was assessed. D, cell growth of LNCaP, PC-3 and DU145 was examined in the presence of BenSer. E, CDK1, CDC20 and UBE2C expression were detected by western blotting in LNCaP and PC-3 cells in the presence of BenSer. F, mTORC1 pathway activation (p-p70S6K) was analyzed in LNCaP and PC-3 cells after BenSer or GPNA treatment after 2h. B, C, Data are the mean ± SEM (n≥3). Mann-Whitney U-test was used to analyze data. D, data are the mean ± SEM (n≥3). Two-way ANOVA test was used to analyze data. *, P<0.05; **, P<0.01; ***, P<0.001.
Figure 3

A

LNCaP

Basal OCR (% of control)

Control  BaeSor  GRNA

B

PC-3

Basal OCR (% of control)

Control  BaeSor  GRNA

C

LNCaP

% CO2 from glutamine relative to control

Control  BaeSor  GRNA

D

PC-3

% CO2 from glutamine relative to control

Control  BaeSor  GRNA

E

LNCaP

Lipid from glutamine relative to control

Control  BaeSor  GRNA

F

PC-3

Lipid from glutamine relative to control

Control  BaeSor  GRNA

G

LNCaP

Relative Intensity of phosphoERK

Control  BaeSor  GRNA  TOFA

H

PC-3

Relative Intensity of phosphoERK

Control  BaeSor  GRNA  TOFA

I

LNCaP

Relative Intensity of neutral lipids

Control  BaeSor  GRNA  TOFA

J

PC-3

Relative Intensity of neutral lipids

Control  BaeSor  GRNA  TOFA

K

LNCaP

Number of droplets/cell

Control  BaeSor  GRNA  TOFA

L

PC-3

Number of droplets/cell

Control  BaeSor  GRNA  TOFA
Figure 3 Inhibition of ASCT2 affects cell metabolism in LNCaP and PC-3 cells. A and B, basal oxygen consumption rate (OCR) was analyzed using a SeaHorse XF Analyzer in LNCaP (A) and PC-3 (B) cells pre-treated with BenSer (10 mM) or GPNA (1 mM). C and D, $^{14}$CO$_2$ generated from glutamine in LNCaP (C) and PC-3 (D) cells was determined after treatment with BenSer (10 mM) or GPNA (1 mM). E and F, lipid generated from glutamine was analyzed in LNCaP (E) and PC-3 (F) cells after treatment with BenSer (10 mM) or GPNA (1 mM). G-J, the mean fluorescence intensities of cellular phospholipids (G and H) and neutral lipids (I and J) were measured in LNCaP (G and I) and PC-3 cells (H and J) after treated for 24 h with BenSer (10 mM), GPNA (1 mM) or TOFA (10 μM). K and L, lipid droplets were measured in LNCaP (K) and PC-3 (L) cells after treatment with BenSer, GPNA or TOFA. A-F, data are the mean ± SEM (n≥3). One-way ANOVA test was used to analyze data. G-L, data are the mean ± SEM (n~300 cells). One-way ANOVA test was used to analyse data. *, $P<0.05$; **, $P<0.01$; ***, $P<0.001$. 
Figure 4

A

Upregulated genes (P<0.05)

<table>
<thead>
<tr>
<th>BenSer</th>
<th>GPNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>1903</td>
<td>635</td>
</tr>
<tr>
<td>521</td>
<td></td>
</tr>
</tbody>
</table>

Downregulated genes (P<0.05)

<table>
<thead>
<tr>
<th>BenSer</th>
<th>GPNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>1699</td>
<td>550</td>
</tr>
<tr>
<td>544</td>
<td></td>
</tr>
</tbody>
</table>

B

RNA Processing Enrichment

<table>
<thead>
<tr>
<th>Enrichment score (ES)</th>
<th>Correlated with control</th>
<th>Correlated with GPNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>ES = 0.471</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P = 0.000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FDR q = 0.025</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C

RNA Processing Enrichment

<table>
<thead>
<tr>
<th>Enrichment score (ES)</th>
<th>Correlated with control</th>
<th>Correlated with BenSer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ES = 0.569</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P = 0.000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FDR q = 1.641</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

D

Cell Cycle Process Enrichment

<table>
<thead>
<tr>
<th>Enrichment score (ES)</th>
<th>Correlated with control</th>
<th>Correlated with GPNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>ES = 0.383</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P = 0.000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FDR q = 0.060</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

E

Cell Cycle Process Enrichment

<table>
<thead>
<tr>
<th>Enrichment score (ES)</th>
<th>Correlated with control</th>
<th>Correlated with BenSer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ES = 0.451</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P = 0.038</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FDR q = 0.0260</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

F

E2F_Q3 Motif Enrichment

<table>
<thead>
<tr>
<th>Enrichment score (ES)</th>
<th>Correlated with control</th>
<th>Correlated with GPNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>ES = 0.389</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P = 0.000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FDR q = 0.044</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

G

E2F_Q3 Motif Enrichment

<table>
<thead>
<tr>
<th>Enrichment score (ES)</th>
<th>Correlated with control</th>
<th>Correlated with BenSer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ES = 0.469</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P = 0.000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FDR q = 0.147</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This article is protected by copyright. All rights reserved
Figure 4. RNA-seq analysis of PC-3 cells treated with BenSer or GPNA. A, Venn diagram of genes up- or down-regulated in both BenSer and GPNA treated groups. B and C, gene set enrichment analysis (GSEA) plot of Gene Ontology categories RNA Processing and Cell Cycle Process in control versus GPNA (1 mM; B) or BenSer (10 mM; C) treatment. D and E, GSEA plot of E2F transcription factor motif gene set in control versus GPNA (1 mM; D) or BenSer (10 mM; E) treatment. F and G, GSEA plot of BCH down-regulated gene set (from [23]) in control versus GPNA (1 mM; F) or BenSer (10 mM; G) treatment groups.
Figure 5

A

ASCT2
GAPDH

shControl
shASCT2#1
shASCT2#2

1.0
0.4
0.1

LNCaP

ASCT2
GAPDH

shControl
shASCT2#1
shASCT2#2

1.0
0.4
0.1

PC-3

B

\[^{1}H\]glutamine uptake (% of control)

shControl
shASCT2#2

LNCaP
PC-3

C

\[^{1}H\]histidine uptake (% of control)

shControl
shASCT2#2

LNCaP
PC-3

D

Relative cell growth (% of day 0)

0 1 2 3

Time (days)

shControl
shASCT2#2

LNCaP

E

Relative cell growth (% of day 0)

0 1 2 3

Time (days)

shControl
shASCT2#2

PC-3

F

BrdU+ cells (%)

shControl
shASCT2#2

PC-3

G

pT369-p70S6K
p70S6K
GAPDH

1.0
0.5

PC-3
**Figure 5 ASCT2 is required for prostate cancer cell proliferation.** 

A, analysis of ASCT2 protein after shRNA knockdown in LNCAP or PC-3 cells using shASCT2#1 or shASCT2#2. 

B and C, analysis of glutamine uptake (B) or leucine uptake (C) in LNCaP or PC-3 cells after shASCT2 knockdown. 

D and E, LNCaP (D) and PC-3 (E) cell growth after shASCT2#2 knockdown was analyzed by MTT assay. 

F and G, cell cycle progression (BrdU incorporation; F) and mTORC1 pathway activation (p-p70S6K; G) was analyzed after shASCT2#2 knockdown in PC-3 cells. 

B-C, F, data are the mean ± SEM (n≥3). Mann-Whitney U-test was used to analyze data. 

D and E, data are the mean ± SEM (n≥3). Significance was assessed using a two-way ANOVA test. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Figure 6

A) Day 2 vs Day 32 images of tumor growth in mice treated with shControl or shASCT2#2.

B) Graph showing tumor growth over time in mice treated with shControl or shASCT2#2.

C) Western blot images showing protein expression levels for pT389, p70S6K, and GAPDH.

D) Bar graph comparing tumor weight between shControl and shASCT2#2 groups.

E) Relative expression levels of pT389, p70S6K, and GAPDH in PC-3 cells.

F) Immunofluorescence images showing expression levels of E2F2, CDK1, CDC20, UBE2C, and Ki67.

G) Bar graph showing total metastasis in liver and lung for shControl and shASCT2#2 groups.

H) Graph showing tumor burden in liver and lung for shControl and shASCT2#2 groups.
Figure 6. ASCT2 is required for tumour growth in vivo. A, PC-3-luc cells stably expressing shControl or shASCT2#2 were injected subcutaneously into the right and left side dorsal flanks of male nude mice. Bioluminescent images are shown at day 2 and day 32. B, Tumour growth was measured twice a week by bioluminescence in shControl (n=10) and shASCT2 (n=8) mice. Data are the mean ± SEM. Significance was assessed using a two-way ANOVA test. ***<0.001. C and D, Tumours (shControl, n=20; shASCT2#2 n=15) were harvested after 32 days, imaged (C) and weighed (D). E, phosphorylated p70S6K was measured after shASCT2 knockdown in PC-3 xenograft. F, sections from shControl and shASCT2 tumours were stained for CDK1, CDC20, UBE2C and Ki67 expression. Representative images, scale bar is 100 µm. G and H, the number (G) and size (H) of spontaneous metastases in liver and lung were measured by bioluminescence. B, Data are the mean ± SEM. Significance was assessed using a two-way ANOVA test. D, H, data are the mean ± SEM. Mann-Whitney U-test is used to analyze data. G, the number of spontaneous metastases at day 32 in shControl and shASCT2 mice was assessed using a two-tailed Fisher exact test. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
<table>
<thead>
<tr>
<th>Dataset</th>
<th>Fold Change</th>
<th>P-value</th>
<th># PCa Samples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Su Multi-cancer</td>
<td>2.36</td>
<td>1.67E-09</td>
<td>26</td>
</tr>
<tr>
<td>Singh Prostate</td>
<td>2.106</td>
<td>3.24E-04</td>
<td>52</td>
</tr>
<tr>
<td>Ramaswamy Multi-cancer</td>
<td>2.087</td>
<td>7.44E-04</td>
<td>10</td>
</tr>
<tr>
<td>Wallace Prostate</td>
<td>1.745</td>
<td>5.11E-04</td>
<td>69</td>
</tr>
<tr>
<td>Magee Prostate</td>
<td>1.518</td>
<td>0.018</td>
<td>8</td>
</tr>
<tr>
<td>Bittner Multi-cancer</td>
<td>1.459</td>
<td>3.64E-12</td>
<td>59</td>
</tr>
<tr>
<td>Welsh Prostate</td>
<td>1.399</td>
<td>7.00E-03</td>
<td>25</td>
</tr>
</tbody>
</table>